Sustainability & Climate

Amid a CEO change, Sherritt International faces a pivotal moment. Can a new leader steer its vital nickel and cobalt assets through volatile markets?

The future of boating isn't just in showrooms. It's in garages where DIYers are driving a quiet, clean-energy revolution on the water. Here's how.

Beyond the $1.2B price tag, Infinity's deal reveals a masterclass in energy M&A, strategic partnerships, and the consolidation of America's shale plays.

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

Amidst record vacancies, a Portland university makes a debt-free move, betting on integrative medicine to revitalize both patients and the city center.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

While the design world embraces white, one company is investing in a full-spectrum color technology, building a resilient market niche.

Designer Hiromi Asai redefines Japanese heritage at Miami Art Week, transforming sacred kimono textiles into sculptural menswear and making a bold market play.

A smart appliance company is upending global expansion by proving that listening to local communities is the key to becoming a brand that truly matters.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

Beneath the glamour of superyacht dining lies a high-stress world. A unique competition is driving innovation in culinary arts and crew wellbeing.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

Whisker's Litter-Robot is now HSA/FSA eligible, a strategic move redefining medical expenses and giving it a major edge in the booming pet tech market.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Beyond the headlines of the G7 tech meeting in Montréal lies a blueprint for Canada's health future, impacting everything from AI diagnostics to local care.